Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Long-Term Deferred Tax (2022 - 2023)

Bicycle Therapeutics (BCYC) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $88.6 million as the latest value for Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax rose 980.45% year-over-year to $88.6 million; the TTM value through Dec 2023 reached $88.6 million, up 980.45%, while the annual FY2023 figure was $88.6 million, 980.45% up from the prior year.
  • Long-Term Deferred Tax hit $88.6 million in Q4 2023 for Bicycle Therapeutics, up from $8.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $88.6 million in Q4 2023 and bottomed at $8.2 million in Q4 2022.